Product Description
GSK2336805 is a hepatitis C virus (HCV) NS5A inhibitor being developed for the treatment of chronic hepatitis C (CHC). (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01439373)
Mechanisms of Action: HCV-NS5A Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Hepatitis C, Chronic|Hepatitis A|Hepatitis C
Phase 1: Hepatitis C|Healthy Volunteers|Hepatitis A
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| HAI117380 | P1 |
Completed |
Hepatitis C |
2014-03-20 |
2019-03-19 |
Treatments |
|
| CR102928 | P1 |
Completed |
Healthy Volunteers |
2014-03-01 |
2019-03-20 |
Treatments |
|
| NCT01458054 | P1 |
Completed |
Hepatitis C |
2011-11-28 |
2019-03-19 |
Treatments |
|
| NCT01424540 | P1 |
Completed |
Hepatitis C |
2011-10-03 |
2019-03-19 |
Treatments |
|
| NCT01277692 | P1 |
Completed |
Hepatitis C|Hepatitis A |
2011-05-09 |
2019-03-19 |
Treatments |
|
| 2012-002555-42 | P2 |
Completed |
Hepatitis C, Chronic |
2016-01-25 |
2022-03-13 |
Treatments |
|
| 2012-000523-40 | P2 |
Completed |
Hepatitis C |
2014-09-11 |
2022-03-13 |
Treatments |
|
| HAI115879 | P2 |
Completed |
Hepatitis C, Chronic|Hepatitis A |
2014-07-01 |
2019-03-19 |
Treatments |
|
| NCT01439373 | P2 |
Completed |
Hepatitis A|Hepatitis C, Chronic |
2011-12-05 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|